Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis.

Mesa RA

Phase1/-2 study of Pomalidomide in myelofibrosis.

Mesa RA, Pardanani AD, Hussein K, Wu W, Schwager S, Litzow MR, Hogan WJ, Tefferi A

Assessing new therapies and their overall impact in myelofibrosis.

Mesa RA

New drugs for the treatment of myelofibrosis.

Mesa RA

Pomalidomide is active in the treatment of anemia associated with myelofibrosis.

Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ, Thiele J, Kvasnicka HM, Vardiman JW, Zhang Y, Bekele BN, Mesa RA, Gale RP, Kantarjian HM

Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.

Mesa RA, Tefferi A

The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis.

Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, Pardanani AD, Steensma DP, Litzow MR, Rivera CE, Camoriano J, Verstovsek S, Sloan J, Harrison C, Kantarjian H, Tefferi A

Itchy mast cells in MPNs.

Mesa RA

How I treat symptomatic splenomegaly in patients with myelofibrosis.

Mesa RA

Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not.

Tefferi A, Mesa RA, Pardanani A, Hussein K, Schwager S, Hanson CA, Steensma DP